1Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by angiotension-eonverting enzyme inhibitor ramipril. Circulation, 2001, 104: 1615--1621.
2Zabalgoitia M. Left ventricular mass and function in primary hypertension. Am J Hypertens, 1996, 9 : 55s--59s.
3Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coil Cardiol, 1992, 19:1550--1558.
4Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of randomized double-blind studio. JAMA, 1996, 275:1505--1513.
5Ritchie RH, Marsh JD, Lancaster WD, et al. Bradykinin blocks angiotension Ⅱ-induced hypertrophy in the presence of endothelial cells.Hypertension, 1998, 31:39--44.
6Ospedale G. Casati, camovali. Clin Ter, 2001, 152 : 103--106.
7Dahlof B. Left ventricular hypertrophy and angiotension Ⅱ antagonist.Am J Hypertens, 2001, 14:174--182.
8Villatico S, Campbell V, Rizzo F, et al. Antihypertensive therapy with losartan and fossinopril: efficacy in left ventricular hypertrophy regression. Am J Hypertens, 1998, 11:125A.
9Thürmann PA, Kenedi P, Harder S, et al. Influence of angiotension Ⅱ antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation, 1998, 98 : 2037--2042.
10Palmieri V, Devereux RB. Angiotension converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hyperterksion. Minerva Gardioagiol, 2002, 50:169--174.
